Loading clinical trials...
Loading clinical trials...
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Intrathecally Administered ALN-SNCA in Participants With Early Parkinson's Disease
Conditions
Interventions
ALN-SNCA
Placebo
Locations
2
Canada
Montreal Neurological Institute and Hospital
Montreal, Quebec, Canada
Center for Human Drug Research
Leiden, South Holland, Netherlands
Start Date
December 5, 2025
Primary Completion Date
June 7, 2029
Completion Date
June 7, 2029
Last Updated
April 14, 2026
NCT06821230
NCT07176494
NCT04335994
NCT05568199
NCT07201610
NCT06671600
Lead Sponsor
Regeneron Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions